Travere Therapeutics Inc share price logo

Travere Therapeutics Inc Share Price

NASDAQ: TVTX

Small Cap

$23.00

-0.47

(-2.00%)

as on

Travere Therapeutics Inc Stock Performance

as on September 16, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $22.52
    $23.5
    downward going graph

    2.09%

    Downside

    2.17%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $12.91
    $28.69
    downward going graph

    43.87%

    Downside

    24.75%

    Upside

    downward going graph

Travere Therapeutics Inc share price movements today

Previous Close
$23.47
Open
$23.32
Volume
1.8M
Day's Low - High
$22.52 - $23.5
52 Week Low - High
$12.91 - $28.69

Travere Therapeutics Inc Historical Returns

1 Month Return
+ 24.71 %
3 Month Return
+ 61.86 %
1 Year Return
+ 74.11 %
3 Year Return
-13.71 %
5 Year Return
+ 20.24 %

Travere Therapeutics Inc Stock Fundamentals & Key Indicators

Check Travere Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

-0.1863

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-120.5M

Revenue (TTM)

333.9M

Profit Margin

-50.64%

Return On Equity TTM

0.00%

Travere Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Travere Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$2.1B20.24%NA-50.64%
BUY$61.1B256.98%-505.15-12.96%
NA$38.7BNANA-3.89%
BUY$101.1B47.85%28.0731.86%
BUY$59.4B-3.43%14.1131.37%

Stock Returns calculator for Travere Therapeutics Inc Stock including INR - Dollar returns

The Travere Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Travere Therapeutics Inc investment value today

Current value as on today

₹1,75,609

Returns

₹75,609

(+75.61%)

Returns from Travere Therapeutics Inc Stock

₹70,623 (+70.62%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on Travere Therapeutics Inc Stock

Based on 22 analysts

BUY

72.73%

Buy

27.27%

Hold

0.00%

Sell

Based on 22 analysts, 72.73% of analysts recommend a 'BUY' rating for Travere Therapeutics Inc. Average target price of $36

Travere Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Travere Therapeutics Inc.

What analysts predicted

36.11%UPSIDE

Target Price

$36

Current Price

$23

Analyzed by

22 Analysts

Target

$36.00

Travere Therapeutics Inc target price $36, a slight upside of 36.11% compared to current price of $23. According to 22 analysts rating.

Travere Therapeutics Inc Stock's Interest Amongst Investors

Search interest for Travere Therapeutics Inc Stock has increased by 800% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:800% versus previous 30 day period

Travere Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
56
59
37
45
41
54
62
74
81
114
Gross Profit
51
57
35
28
39
41
61
72
77
98
Operating Income
-80
-87
-89
-82
-139
-67
-54
-60
-41
-12
EBITDA
-90
-93
-74
-73
-123
-56
-40
-45
-25
-12
Interest Expense
2
2
2
2
2
2
2
2
2
2
Depreciation
9
13
5
9
9
10
11
12
12
14
Income Before Tax
-86
-85
-89
-88
-135
-69
-54
-60
-41
-12
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-86
-85
150
-90
-136
-70
-54
-60
-41
-12
Net Profit Margin
-151.48%
-143.44%
406.35%
-200.12%
-328.86%
-130.11%
-87.14%
-80.58%
-50.44%
-11.14%

Travere Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
99
133
154
164
175
198
227
212
145
233
Gross Profit
97
129
151
158
170
192
220
204
133
225
Operating Income
-50
-58
-53
-80
-99
-75
-139
-251
-376
-320
EBITDA
129
-38
-38
-73
-107
-143
-186
-299
-326
-265
Interest Expense
19
4
4
9
18
19
19
11
11
11
Depreciation
-
-
17
18
20
24
26
33
38
43
Income Before Tax
105
-57
-58
-101
-146
-188
-179
-278
-376
-320
Income Tax Expense
-11
-9
1
0
0
-19
0
0
0
0
Net Income
117
-47
-59
-102
-146
-169
-180
-278
-111
-321
Net Profit Margin
117.36%
-35.86%
-38.55%
-62.51%
-83.51%
-85.43%
-79.16%
-131.35%
-76.70%
-137.90%

Travere Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-85
-115
-88
-136
-69
-54
-60
-41
-12
Operating Cash Flow
-69
-59
-70
-119
-40
-42
-35
-42
4
Investing Cash Flow
-23
133
-16
104
28
46
-80
41
4
Financing Cash Flow
2
0
0
0
0
0
139
3
1
Change in Cash
-90
73
-86
-14
-10
4
22
3
13

Travere Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-47
-59
-102
-146
-169
-180
-278
-376
-320
Operating Cash Flow
-1
7
-24
-58
-42
-14
-186
-280
-237
Investing Cash Flow
10
45
-203
19
-61
-137
-32
55
99
Financing Cash Flow
-5
5
231
-2
127
231
117
218
139
Change in Cash
3
58
3
-40
22
80
-104
-3
0

Global Institutional Holdings in Travere Therapeutics Inc

Funds
Holdings
Armistice Capital, LLC
9.95%
BlackRock Inc
9.19%
HHG PLC
8.45%
Vanguard Group Inc
5.62%
Macquarie Group Ltd
5.38%

Travere Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 11 September

    Thu, 04:33 PM

    -

    Wells Fargo raises Travere Therapeutics price target to $35, citing increased confidence in FSGS approval.

Insights on Travere Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -60.26M → -12.75M (in $), with an average increase of 134.7% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 6 quarters, 41.37M → 114.44M (in $), with an average increase of 18.1% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, TVTX stock has moved up by 22.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 129.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 70.6% return, outperforming this stock by 9.4%

About Travere Therapeutics Inc

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
OrganisationTravere Therapeutics Inc
Headquarters3611 Valley Centre Drive, San Diego, CA, United States, 92130
IndustryHealth Technology
CEODr. Eric M. Dube Ph.D.
E-voting on sharesClick here to vote

Key Management of Travere Therapeutics Inc

Name

Title

Ms. Sandra Calvin

SVP, Corporate Controller & Chief Accounting Officer

Mr. Casey Logan

Chief Business Officer

Mr. Christopher Cline C.F.A.

Chief Financial Officer

Dr. Jula Inrig M.D.

Chief Medical Officer

Mr. Peter Heerma

Chief Commercial Officer

Ms. Nivi Nehra

Vice President of Corporate Communications & Investor Relations

Ms. Elizabeth E. Reed J.D.

Chief Legal Officer, General Counsel & Secretary

Ms. Angela Giannantonio

Chief People Officer

Dr. Eric M. Dube Ph.D.

President, CEO & Director

Dr. William E. Rote Ph.D.

Chief Research Officer

FAQs

What is Travere Therapeutics Inc share price today?

Travere Therapeutics Inc share price today is $23 as on at the close of the market. Travere Therapeutics Inc share today touched a day high of $23.5 and a low of $22.52.

What is the 52 week high and 52 week low for Travere Therapeutics Inc share?

Travere Therapeutics Inc share touched a 52 week high of $28.69 on and a 52 week low of $12.91 on . Travere Therapeutics Inc stock price today i.e. is closed at $23,which is 19.84% down from its 52 week high and 78.16% up from its 52 week low.

What is Travere Therapeutics Inc's market capitalisation today?

Travere Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Travere Therapeutics Inc Stock (TVTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Travere Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Travere Therapeutics Inc Shares that will get you 0.0652 shares as per Travere Therapeutics Inc share price of $23 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Travere Therapeutics Inc Stock (TVTX) from India?

Indian investors can start investing in Travere Therapeutics Inc (TVTX) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Travere Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Travere Therapeutics Inc share’s latest price of $23 as on September 16, 2025 at 1:29 am IST, you will get 0.4348 shares of Travere Therapeutics Inc. Learn more about fractional shares .

What are the returns that Travere Therapeutics Inc has given to Indian investors in the last 5 years?

Travere Therapeutics Inc stock has given 20.24% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?